Nasdaq
$31.15▼ 0.84%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.17BShares out 69.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
42- 10.13After-hours26.10.14 05:104Ownership#●●●
Pharvaris N.V.
Insider Lu Peng of Pharvaris N.V. reported a change in beneficial ownership of securities as of October 11, 2026. This filing serves as an official notification to the SEC regarding executive stock transactions and internal holdings.…more
$31.15-0.84%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.25Regular26.09.26 02:354Ownership
Pharvaris N.V.
Director Viviane Monges of Pharvaris N.V. filed a Form 4 report regarding changes in her beneficial ownership of company securities as of September 23, 2026. This filing serves as an official disclosure of insider stock transactions.…more
$31.15-0.84%vs prev closeView filingShare - 9.24After-hours26.09.25 05:034Ownership
Pharvaris N.V.
Insider Lu Peng of Pharvaris N.V. filed a Form 4 report regarding a change in beneficial ownership of securities as of September 22, 2026. This filing serves as a standard disclosure of insider transaction activity and does not involve material financial events such as capital raises or delisting.…more
$31.15-0.84%vs prev closeView filingShare
41 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.9Overnight26.10.09 16:05#●●●#●●●#●●●
Pharvaris Reports Positive Phase 3 Data for HAE Treatment Deucrictibant…more
Pharvaris announced that its Phase 3 trial for deucrictibant showed rapid symptom relief for HAE attacks. The drug is currently under regulatory review in the U.S. and Europe for potential approval.…more
$31.15-0.84%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.8After-hours26.10.09 07:35
●●●●●●●● ●●●●● ●●●●●●
Pharvaris announced that Phase 3 study results for its oral HAE treatment, deucrictibant, have been published in The Lancet. While the drug is currently under regulatory review by the FDA and EMA, its ultimate commercial success remains subject to final approval.…more
$31.15-0.84%vs prev close - 10.5Pre-market26.10.05 19:50
●●●●●●●● ●●●●● ●●●●●●
Pharvaris published study findings in Advances in Therapy highlighting persistent gaps in hereditary angioedema treatment satisfaction and patient needs. The analysis underscores the importance of addressing real-world treatment burdens to improve patient outcomes.…more
$31.15-0.84%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report